Rhythm Pharmaceuticals (RYTM) Financials

Rhythm Pharmaceuticals’ latest quarter shows strong revenue growth, but the company is still operating at a sizable loss and remains dependent on its cash and investment portfolio to fund the business.

For Q1 2026, Rhythm reported revenue of $60.1 million, up from $57.3 million in Q4 2025 and $48.5 million in Q2 2025. That continues a longer-term upward trend from $32.7 million in Q1 2025 and $11.5 million in Q1 2023. Gross profit also remained strong at $53.0 million, with gross margin still very healthy for a commercial-stage biotech company.

At the same time, operating expenses remain heavy. In Q1 2026, SG&A was $63.6 million and R&D was $41.7 million, resulting in an operating loss of $52.4 million. Net loss came in at $55.6 million, essentially in line with the losses reported across the last several quarters.

The balance sheet remains a key point for investors. Rhythm ended Q1 2026 with $62.1 million in cash, $278.5 million in short-term investments, and $2.5 million in long-term investments, for a total of roughly $343 million in cash and investments. That is down from the prior year’s higher cash balance, but still gives the company meaningful liquidity.

• Revenue continues to scale: Q1 2026 revenue of $60.1 million was above the prior quarters shown, extending a multi-year growth trend.
• Gross profit remains robust: Q1 2026 gross profit of $53.0 million suggests the company is still generating strong product-level economics.
• Strong liquidity cushion: Cash plus investments totaled about $343 million at the end of Q1 2026, providing runway.
• Operating cash burn improved versus some earlier periods: Cash used in operations was $44.2 million in Q1 2026, better than some of the more cash-intensive quarters in 2024.
• Investment portfolio still supports the business: The company generated $57.1 million of net cash from investing activities in Q1 2026, helped by maturities and sales of investments.
• Debt burden is present but manageable for now: Rhythm had $10.1 million of short-term debt and $98.3 million of long-term debt at quarter-end.
• Share count remains elevated: Weighted average shares outstanding were about 67.9 million in Q1 2026, limiting EPS leverage.
• Losses remain large: Q1 2026 net loss of $55.6 million shows profitability is still far away.
• Operating expenses are very high: Combined SG&A and R&D exceeded $105 million in Q1 2026, overwhelming gross profit.
• Equity has been volatile and diluted by capital raises: The company has repeatedly issued common equity over the last several years to support operations and growth.

Looking at the broader pattern since 2023, Rhythm has clearly improved its top line, but it has not yet converted that growth into net income. Revenue has expanded materially, while operating losses have stayed in the $40 million to $55 million range on a quarterly basis. The business appears to be in a commercialization-and-expansion phase rather than a profitability phase.

Another important trend is the balance sheet mix. Cash and investments have fallen from prior highs, but remain substantial. That said, the company has also carried significant liabilities and redeemable noncontrolling interest balances, so investors should monitor whether revenue growth continues to outpace cash burn over the next several quarters.

Bottom line: Rhythm Pharmaceuticals is showing encouraging revenue momentum and solid gross profit, but the stock still depends on continued commercial execution and eventual operating leverage. For retail investors, the key question is whether the company can keep growing revenue fast enough to narrow losses before its cash runway becomes more pressured.